This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In “Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark,” Papp et al. reported that using the 2015 International Panel for NMO Diagnosis (IPND) criteria, the prevalence of NMO spectrum disorder (NMOSD) in Denmark in persons older than 16 years is 1.09 per 100,000 persons. They noted that this rate is higher than that reported in previous studies in Australia/New Zealand (0.7) and Catalonia (0.89) and lower than that reported in previous studies in Region of Southern Denmark (4.4) and Olmsted County, Minnesota (3.9). Asgari and Flanagan, who authored the articles from Region of Southern Denmark and Olmsted County, respectively, believe that Papp et al.'s calculation of the prevalence of NMOSD is low because of the (1) exclusion of 16 patients who were seropositive for aquaporin-4 IgG, (2) use of aquaporin-4 IgG data from multiple rather than a single laboratory, some of which used a less sensitive assay, and (3) use of only 2 (rather than all) of the core clinical criteria for NMOSD. Papp et al. respond that (1) their findings actually fall within Flanagan et al.'s wide interquartile range (0.8–7.1) and that (2) the 2015 IPND criteria emphasize exclusion of alternative diagnoses and all excluded seropositive cases were inconsistent with NMOSD due to weak positivity, features consistent with MS, good response to disease-modifying therapy, or long-term stability without treatment. It is clear that estimates of NMOSD prevalence vary depending on the criteria used to define NMOSD and the study population. Nonetheless, it seems to consistently be less than 5 per 100,000 persons in the regions studied.
In “Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark,” Papp et al. reported that using the 2015 International Panel for NMO Diagnosis (IPND) criteria, the prevalence of NMO spectrum disorder (NMOSD) in Denmark in persons older than 16 years is 1.09 per 100,000 persons. They noted that this rate is higher than that reported in previous studies in Australia/New Zealand (0.7) and Catalonia (0.89) and lower than that reported in previous studies in Region of Southern Denmark (4.4) and Olmsted County, Minnesota (3.9). Asgari and Flanagan, who authored the articles from Region of Southern Denmark and Olmsted County, respectively, believe that Papp et al.'s calculation of the prevalence of NMOSD is low because of the (1) exclusion of 16 patients who were seropositive for aquaporin-4 IgG, (2) use of aquaporin-4 IgG data from multiple rather than a single laboratory, some of which used a less sensitive assay, and (3) use of only 2 (rather than all) of the core clinical criteria for NMOSD. Papp et al. respond that (1) their findings actually fall within Flanagan et al.'s wide interquartile range (0.8–7.1) and that (2) the 2015 IPND criteria emphasize exclusion of alternative diagnoses and all excluded seropositive cases were inconsistent with NMOSD due to weak positivity, features consistent with MS, good response to disease-modifying therapy, or long-term stability without treatment. It is clear that estimates of NMOSD prevalence vary depending on the criteria used to define NMOSD and the study population. Nonetheless, it seems to consistently be less than 5 per 100,000 persons in the regions studied.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
